Comparing iNOS levels in the dermis and granuloma across the Ridley-Jopling spectrum shows a clear trend with highest levels in the dermis and granuloma of BT patients and lowest levels in the LL patients (skin iNOS dermis BT 47.7%, BL 36.4% and LL 15.9%; skin iNOS granuloma BT 45.3%, BL 39.0% and LL 32.1%; p<0.05). The gene discussed is NOS2; the disease is Granuloma.